4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 4 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Shingrix®: new trials by email Literature Review of Shingrix® trials Research Report on Shingrix®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ) | Phase 1 | Recruiting | Guangzhou Patronus Biotech Co., Ltd. | 92 | 2025-03-13 | 2025-04-01 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Placebo control: Saline - Herpes Zoster | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 540 | 2025-02-15 | 2025-01-30 |
| Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation - Rheumatoid Arthritis, Spondylitis, Ankylosing | Phase 4 | Active not recruiting | University of Sao Paulo General Hospital | 2005 | 2023-05-23 | 2026-05-04 |
| Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control - Herpes Zoster | Phase 2 | Completed | MAXVAX Biotechnology Limited Liability Company | 924 | 2023-05-07 | 2026-10-15 |
| Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant - Herpes Zoster | Phase 1 | Completed | MAXVAX Biotechnology Limited Liability Company | 132 | 2022-12-07 | 2026-10-15 |
| Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients recombinant zoster vaccine - Shingles, Zoster | Phase 4 | Unknown | Prof Patrice Lalive | 100 | 2022-12-01 | 2024-04-10 |
| Simultaneous RZV and aIIV4 Vaccination FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX® - Pain, Quality of Life | Phase 4 | Completed | Duke University | 267 | 2021-09-21 | 2024-07-11 |
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
Herpes Zoster (7) · Chickenpox (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Dermatomyositis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Influenza, Human (1) · Injection Site Reaction (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Myositis (1) · Pain (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
MAXVAX Biotechnology Limited Liability Company (2) · Duke University (1) · Emory University (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Prof Patrice Lalive (1) · Sinocelltech Ltd. (1) · University of Sao Paulo General Hospital (1)
China (4) · United States (2) · Brazil (1) · Switzerland (1)
Yanxia Wang (2) · Arnaud Didierlaurent, Pr (1) · Kenneth Schmader, MD (1) · Nadine Rouphael, MD (1) · Patrice Lalive, Pr (1) · Renfeng Fan (1)
PMID 37781954, PMID 39446325, PMID 41679320, PMID 41932224, PMID 42261247, PMID 42294825, PMID 42843284
U19AI090023 (1)